Reply to Scalone and Cortesi: "Cost-utility analysis of biologic therapies to treat chronic plaque psoriasis in Italy: the importance of using updated and adequate social tariffs to calculate QALYs"
BioDrugs
.
2015 Feb;29(1):71-2.
doi: 10.1007/s40259-015-0118-5.
Authors
Federico Spandonaro
1
,
Fabio Ayala
,
Enzo Berardesca
,
Sergio Chimenti
,
Giampiero Girolomoni
,
Patrizia Martini
,
Andrea Peserico
,
Barbara Polistena
,
Antonio Puglisi Guerra
,
Gino Antonio Vena
,
Gianfranco Altomare
,
Piergiacomo Calzavara Pinton
Affiliation
1
University of Rome Tor Vergata, Via Columbia 2, 00133, Rome, Italy, federico.spandonaro@uniroma2.it.
PMID:
25647521
DOI:
10.1007/s40259-015-0118-5
No abstract available
Publication types
Letter
Comment
MeSH terms
Biological Therapy / economics*
Female
Humans
Male
Psoriasis / drug therapy*
Psoriasis / economics*